Pembrolizumab monotherapy was at the time of this study FDA-approved as first-line therapy for patients with EGFR/ALK wild-type aNSCLC and PD-L1 Tumor Proportion score (TPS) ≥50% (8), and 24 of the 39 patients with PD-L1 status available had TPS ≥50%. Here, ALK is linked to neoplasm.